Sarcoma in patients with Lynch syndrome and response to immunotherapy
- 27 December 2023
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 129 (4) , 820-826
Abstract
Background: Lynch syndrome (LS) is an autosomal dominant genetic predisposition to multiple malignancies and is characterized by deficient DNA mismatch repair. Increased incidence of sarcomas is not formally ascribed to LS; however, increasing evidence suggests a preponderance of these malignancies in affected families. Sarcomas typically possess a low tumor mutational burden and incite a poor immune infiltrate, thereby rendering them poorly responsive to immunotherapy.Methods: We searched the University of California, Los Angeles (UCLA) sarcoma program database for patients with a diagnosis of sarcoma and LS from 2016 to 2023. Three such patients were identified and all three were treated with PD1 blockade.Results: We present three cases of LS‐associated sarcomas (two soft tissue sarcoma and one osteosarcoma) with increased tumor mutational burdens. These patients were each treated with an anti‐PD1 antibody and experienced a response far superior to that reported for non‐LS‐associated sarcomas.Conclusions: Increased mutational burden and immune infiltrate are observed for sarcomas associated with LS. Although unselected patients with sarcoma have demonstrated poor response rates to immunotherapy, our findings suggest that patients with Lynch‐associated sarcomas are more likely to respond to treatment with anti‐PD1. These patients should be given consideration for immunotherapy.Keywords
This publication has 15 references indexed in Scilit:
- Analysis in the Prospective Lynch Syndrome Database identifies sarcoma as part of the Lynch syndrome tumor spectrumInternational Journal of Cancer, 2020
- Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to PembrolizumabClinical Cancer Research, 2020
- The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered researchNature Medicine, 2020
- Immunotherapy in colorectal cancer: rationale, challenges and potentialNature Reviews Gastroenterology & Hepatology, 2019
- Chemoresistant pleomorphic rhabdomyosarcoma: whole exome sequencing reveals underlying cancer predisposition and therapeutic optionsJournal of Medical Genetics, 2018
- Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trialsThe Lancet Oncology, 2018
- Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue SarcomasCell, 2017
- Milestones of Lynch syndrome: 1895–2015Nature Reviews Cancer, 2015
- Sarcomas associated with hereditary nonpolyposis colorectal cancer: broad anatomical and morphological spectrumFamilial Cancer, 2009
- Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastasesBritish Journal of Cancer, 2005